EA201491460A1 - ПРИМЕНЕНИЕ ЛАХИНИМОДА В ЛЕЧЕНИИ ПАЦИЕНТОВ С БОЛЕЗНЬЮ КРОНА, У КОТОРЫХ НЕ ЭФФЕКТИВНА ТЕРАПИЯ ПЕРВОЙ ЛИНИИ АНТИ-TNFα - Google Patents
ПРИМЕНЕНИЕ ЛАХИНИМОДА В ЛЕЧЕНИИ ПАЦИЕНТОВ С БОЛЕЗНЬЮ КРОНА, У КОТОРЫХ НЕ ЭФФЕКТИВНА ТЕРАПИЯ ПЕРВОЙ ЛИНИИ АНТИ-TNFαInfo
- Publication number
- EA201491460A1 EA201491460A1 EA201491460A EA201491460A EA201491460A1 EA 201491460 A1 EA201491460 A1 EA 201491460A1 EA 201491460 A EA201491460 A EA 201491460A EA 201491460 A EA201491460 A EA 201491460A EA 201491460 A1 EA201491460 A1 EA 201491460A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- patient
- disease
- crohn
- tnfα
- lachinimode
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 208000011231 Crohn disease Diseases 0.000 abstract 4
- 238000000034 method Methods 0.000 abstract 3
- 230000006698 induction Effects 0.000 abstract 1
- 238000012423 maintenance Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 238000001356 surgical procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
- C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261595006P | 2012-02-03 | 2012-02-03 | |
| PCT/US2013/024356 WO2013116657A1 (en) | 2012-02-03 | 2013-02-01 | USE OF LAQUINIMOD FOR TREATING CROHN'S DISEASE PATIENTS WHO FAILED FIRST-LINE ANTI-TNFα THERAPY |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201491460A1 true EA201491460A1 (ru) | 2015-01-30 |
Family
ID=48903432
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201491460A EA201491460A1 (ru) | 2012-02-03 | 2013-02-01 | ПРИМЕНЕНИЕ ЛАХИНИМОДА В ЛЕЧЕНИИ ПАЦИЕНТОВ С БОЛЕЗНЬЮ КРОНА, У КОТОРЫХ НЕ ЭФФЕКТИВНА ТЕРАПИЯ ПЕРВОЙ ЛИНИИ АНТИ-TNFα |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US9161935B2 (enExample) |
| EP (1) | EP2811832A4 (enExample) |
| JP (2) | JP2015505564A (enExample) |
| KR (1) | KR20140138694A (enExample) |
| CN (2) | CN104093310A (enExample) |
| AR (1) | AR089862A1 (enExample) |
| AU (2) | AU2013214909A1 (enExample) |
| BR (1) | BR112014018485A8 (enExample) |
| CA (1) | CA2862865A1 (enExample) |
| EA (1) | EA201491460A1 (enExample) |
| HK (1) | HK1202776A1 (enExample) |
| IL (1) | IL233557A0 (enExample) |
| MX (1) | MX2014009373A (enExample) |
| SG (1) | SG11201404214QA (enExample) |
| TW (1) | TW201345527A (enExample) |
| WO (1) | WO2013116657A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2234485B1 (en) | 2007-12-20 | 2013-11-13 | Teva Pharmaceutical Industries, Ltd. | Stable laquinimod preparations |
| SG10201500639TA (en) | 2010-01-27 | 2015-03-30 | Arena Pharm Inc | Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof |
| HK1199820A1 (en) | 2011-10-12 | 2015-07-24 | Teva Pharmaceutical Industries Ltd. | Treatment of multiple sclerosis with combination of laquinimod and fingolimod |
| EP2744498A4 (en) | 2012-02-16 | 2014-12-03 | Teva Pharma | N-ETHYL-N-PHENYL-1,2-DIHYDRO-4,5-DI-HYDROXY-1-METHYL-2-OXO-3-CHINOLINE CARBOXAMIDE AND THE PREPARATION AND USE THEREOF |
| TW201400117A (zh) | 2012-06-05 | 2014-01-01 | Teva Pharma | 使用拉喹莫德治療眼發炎疾病 |
| TW201410244A (zh) | 2012-08-13 | 2014-03-16 | Teva Pharma | 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ） |
| HK1215210A1 (zh) | 2012-11-07 | 2016-08-19 | Teva Pharmaceutical Industries Ltd. | 拉喹莫德胺盐 |
| CA2901849A1 (en) | 2013-03-14 | 2014-09-25 | Teva Pharmaceutical Industries Ltd. | Crystals of laquinimod sodium and improved process for the manufacture thereof |
| EP3094330A4 (en) * | 2014-01-17 | 2017-09-27 | Teva Pharmaceutical Industries Ltd | Treatment of crohn's disease using low doses of laquinimod |
| SG11201608674UA (en) | 2014-04-29 | 2016-11-29 | Teva Pharma | Laquinimod for the treatment of relapsing-remitting multiple sclerosis (rrms) patients with a high disability status |
| AU2016284162A1 (en) | 2015-06-22 | 2018-02-01 | Arena Pharmaceuticals, Inc. | Crystalline L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid(Compound1) for use in SIP1 receptor-associated disorders |
| JP6909208B2 (ja) * | 2015-09-17 | 2021-07-28 | アムジェン インコーポレイテッド | Ｉｌ２３経路バイオマーカーを使用するｉｌ２３アンタゴニストに対する臨床応答の予測 |
| AU2018220521A1 (en) | 2017-02-16 | 2019-09-05 | Arena Pharmaceuticals, Inc. | Compounds and methods for treatment of primary biliary cholangitis |
| CA3053416A1 (en) | 2017-02-16 | 2018-08-23 | Arena Pharmaceuticals, Inc. | Compounds and methods for treatment of inflammatory bowel disease with extra-intestinal manifestations |
| WO2019236757A1 (en) | 2018-06-06 | 2019-12-12 | Arena Pharmaceuticals, Inc. | Methods of treating conditions related to the s1p1 receptor |
| CN113226307A (zh) * | 2018-11-30 | 2021-08-06 | 艾尼纳制药公司 | 治疗与s1p1受体有关的病况的方法 |
Family Cites Families (97)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3024257A (en) | 1961-04-10 | 1962-03-06 | Frosst & Co Charles E | Stable preparations of alkali metal salts of estrone sulfate |
| FR2340735A1 (fr) | 1976-02-11 | 1977-09-09 | Roussel Uclaf | Nouveaux derives de l'acide 3-quinoleine carboxylique, leur procede de preparation et leur application comme medicament |
| IE52670B1 (en) | 1981-03-03 | 1988-01-20 | Leo Ab | Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation |
| DE3437232A1 (de) | 1984-10-10 | 1986-04-17 | Mack Chem Pharm | Stabilisierte injektionsloesungen von piroxicam |
| US4782155A (en) | 1986-03-19 | 1988-11-01 | Banyu Pharmaceutical Co., Ltd. | Cephalosporin derivatives, processes for their preparation and antibacterial agents |
| US5139878A (en) | 1991-08-12 | 1992-08-18 | Allied-Signal Inc. | Multilayer film constructions |
| US5540934A (en) | 1994-06-22 | 1996-07-30 | Touitou; Elka | Compositions for applying active substances to or through the skin |
| US5912349A (en) | 1997-01-31 | 1999-06-15 | Pharmacia & Upjohn Company | Process for the preparation of roquinimex |
| US20030124187A1 (en) | 1997-02-14 | 2003-07-03 | Smithkline Beecham Laboratoires Pharmaceutiques, | Pharmaceutical formulations comprising amoxycillin and clavulanate |
| US6696407B1 (en) | 1997-03-21 | 2004-02-24 | The Regents Of The University Of California | Huntington's disease treatment comprising administering aldose reductase inhibitors to increase striatal CNTF |
| GB9726339D0 (en) | 1997-12-13 | 1998-02-11 | Zeneca Ltd | Human-derived tissue-specific potassium channel |
| US6077851A (en) | 1998-04-27 | 2000-06-20 | Active Biotech Ab | Quinoline derivatives |
| SE9801474D0 (sv) * | 1998-04-27 | 1998-04-27 | Active Biotech Ab | Quinoline Derivatives |
| US6133285A (en) | 1998-07-15 | 2000-10-17 | Active Biotech Ab | Quinoline derivatives |
| SE9802550D0 (sv) | 1998-07-15 | 1998-07-15 | Active Biotech Ab | Quinoline derivatives |
| US6121287A (en) | 1998-07-15 | 2000-09-19 | Active Biotech Ab | Quinoline derivatives |
| SE9802549D0 (sv) | 1998-07-15 | 1998-07-15 | Active Biotech Ab | Quinoline derivatives |
| US6395750B1 (en) | 1999-10-25 | 2002-05-28 | Active Biotech Ab | Drugs for the treatment of malignant tumors |
| WO2002007757A2 (en) | 2000-07-21 | 2002-01-31 | Lue Tom F | Prevention and treatment of sexual arousal disorders |
| US6307050B1 (en) | 2000-08-29 | 2001-10-23 | R. T. Alamo Venture I Llc | Method of synthesizing flosequinan from 4-fluoroanthranilic acid |
| US6802422B2 (en) | 2000-12-12 | 2004-10-12 | Multi-Comp, Inc. | Sealed blister assembly |
| US6706733B2 (en) | 2001-05-08 | 2004-03-16 | Dainippon Ink And Chemicals, Inc. | Quinolinone derivative formulation and its production method |
| US20030119826A1 (en) | 2001-09-24 | 2003-06-26 | Pharmacia Corporation | Neuroprotective treatment methods using selective iNOS inhibitors |
| US6875869B2 (en) | 2002-06-12 | 2005-04-05 | Active Biotech Ab | Process for the manufacture of quinoline derivatives |
| US7560557B2 (en) | 2002-06-12 | 2009-07-14 | Active Biotech Ag | Process for the manufacture of quinoline derivatives |
| SE0201778D0 (sv) | 2002-06-12 | 2002-06-12 | Active Biotech Ab | Process for the manufacture of quinoline derivatives |
| ES2282667T3 (es) | 2002-06-25 | 2007-10-16 | Merck Frosst Canada Ltd. | Inhibidores de pde4 8-(biaril)quinolinas. |
| US7820145B2 (en) | 2003-08-04 | 2010-10-26 | Foamix Ltd. | Oleaginous pharmaceutical and cosmetic foam |
| US20070292461A1 (en) | 2003-08-04 | 2007-12-20 | Foamix Ltd. | Oleaginous pharmaceutical and cosmetic foam |
| US7790197B2 (en) | 2003-06-09 | 2010-09-07 | Warner-Lambert Company Llc | Pharmaceutical compositions of atorvastatin |
| US20050271717A1 (en) | 2003-06-12 | 2005-12-08 | Alfred Berchielli | Pharmaceutical compositions of atorvastatin |
| WO2005000246A2 (en) | 2003-06-25 | 2005-01-06 | Elan Pharmaceuticals, Inc. | Methods and compositions for treating rheumatoid arthritis |
| US8795693B2 (en) | 2003-08-04 | 2014-08-05 | Foamix Ltd. | Compositions with modulating agents |
| SE0400235D0 (sv) | 2004-02-06 | 2004-02-06 | Active Biotech Ab | New composition containing quinoline compounds |
| US8314124B2 (en) | 2004-02-06 | 2012-11-20 | Active Biotech Ab | Crystalline salts of quinoline compounds and methods for preparing them |
| US20060004019A1 (en) | 2004-04-01 | 2006-01-05 | Ivan Lieberburg | Steroid sparing agents and methods of using same |
| WO2006029036A2 (en) | 2004-09-02 | 2006-03-16 | Teva Pharmaceutical Industries, Ltd. | Combination therapy with glatiramer acetate and n-acetylcysteine for the treatment of multiple sclerosis |
| WO2006029411A2 (en) | 2004-09-09 | 2006-03-16 | Yeda Research And Development Co. Ltd. | Mixtures of polypeptides, compositions containing and processes for preparing same, and uses thereof |
| US20060205822A1 (en) | 2004-12-22 | 2006-09-14 | Forest Laboratories, Inc. | 1-Aminocyclohexane derivatives for the treatment of multiple sclerosis, emotional lability and pseudobulbar affect |
| WO2006076681A2 (en) | 2005-01-13 | 2006-07-20 | Sirtris Pharmaceuticals, Inc. | Novel compositions for preventing and treating neurodegenerative and blood coagulation disorders |
| PL1902034T3 (pl) | 2005-06-02 | 2011-09-30 | Glenmark Pharmaceuticals Sa | Nowe ligandy receptorów kanabinoidowych, kompozycja farmaceutyczna je zawierająca oraz proces ich wytwarzania |
| US9168286B2 (en) | 2005-10-13 | 2015-10-27 | Human Genome Sciences, Inc. | Methods and compositions for use in treatment of patients with autoantibody positive disease |
| CA2626082C (en) | 2005-10-13 | 2017-04-11 | Human Genome Sciences, Inc. | Methods and compositions for use in treatment of patients with autoantibody positive disease |
| EP2687512A1 (en) | 2005-10-19 | 2014-01-22 | Teva Pharmaceutical Industries Ltd. | Crystals of Laquinimod Sodium, and Process for the Manufacture Thereof |
| JP5203956B2 (ja) | 2005-10-26 | 2013-06-05 | メルク セローノ ソシエテ アノニム | メタロプロテイナーゼの調節のためのスルホンアミド誘導体とその使用 |
| US20080108641A1 (en) | 2006-02-08 | 2008-05-08 | Ajami Alfred M | Compounds for treating inflammatory disorders, demyelinating disdorders and cancers |
| US8367629B2 (en) | 2006-02-14 | 2013-02-05 | Noxxon Pharma Ag | MCP-1 binding nucleic acids and use thereof |
| ES2752137T3 (es) * | 2006-02-28 | 2020-04-03 | Biogen Ma Inc | Métodos para tratar enfermedades inflamatorias y autoinmunes con natalizumab |
| US8410115B2 (en) | 2006-02-28 | 2013-04-02 | Elan Pharmaceuticals, Inc. | Methods of treating inflammatory and autoimmune diseases with alpha-4 inhibitory compounds |
| WO2007103112A2 (en) | 2006-03-03 | 2007-09-13 | Elan Pharmaceuticals, Inc. | Methods of treating inflammatory and autoimmune diseases with natalizumab |
| AU2007227609A1 (en) | 2006-03-16 | 2007-09-27 | Genentech, Inc. | Methods of treating lupus using CD4 antibodies |
| WO2007120656A2 (en) | 2006-04-10 | 2007-10-25 | Abbott Biotechnology Ltd. | Uses and compositions for treatment of rheumatoid arthritis |
| US20080118553A1 (en) | 2006-06-12 | 2008-05-22 | Anton Frenkel | Tannate salt form of polypeptide mixtures, their preparation and use |
| US7989473B2 (en) | 2006-06-12 | 2011-08-02 | Teva Pharmaceutical Industries, Ltd. | Stable laquinimod preparations |
| CA2657716A1 (en) | 2006-07-17 | 2008-01-24 | Novartis Ag | Cholanic acid amides |
| EP1886996A1 (en) | 2006-08-10 | 2008-02-13 | Ferrer Internacional, S.A. | 1H-Quinolin-4-one compounds, with affinity for the GABA receptor, processes, uses and compositions |
| US20080090897A1 (en) | 2006-08-11 | 2008-04-17 | The Johns Hopkins University | Compositions and methods for neuroprotectin |
| JP5216769B2 (ja) | 2006-08-17 | 2013-06-19 | ザ・ユニバーシティ・オブ・シカゴ | 炎症性疾患の処置 |
| WO2008085484A2 (en) | 2006-12-28 | 2008-07-17 | Jacobus Pharmaceutical Company, Inc. | Treatment of inflammatory bowel disease with enteric coated formulations comprising 5-aminosalicylic acid or 4-aminosalicylic acid |
| US8138201B2 (en) | 2007-07-11 | 2012-03-20 | Medicinova, Inc. | Treatment of progressive neurodegenerative disease with ibudilast |
| WO2009053070A1 (en) | 2007-10-23 | 2009-04-30 | Schwarz Pharma Ag | Compounds for treating demyelination conditions |
| EP2234485B1 (en) | 2007-12-20 | 2013-11-13 | Teva Pharmaceutical Industries, Ltd. | Stable laquinimod preparations |
| ES2329327B1 (es) | 2008-03-19 | 2010-09-17 | Proyecto De Biomedicina Cima, S.L. | Combinaciones sinergicas de 5'-metiltioadenosina. |
| UA104005C2 (ru) | 2008-09-03 | 2013-12-25 | Тева Фармасьютикл Индастриз, Лтд. | 2-оксо-1,2-дигидрохинолиновые модуляторы иммунной функции |
| TW201438738A (zh) | 2008-09-16 | 2014-10-16 | Genentech Inc | 治療進展型多發性硬化症之方法 |
| TWI404721B (zh) | 2009-01-26 | 2013-08-11 | Pfizer | 胺基－雜環化合物 |
| UY32427A (es) | 2009-02-13 | 2010-09-30 | Boheringer Ingelheim Internat Gmbh | Composicion farmaceutica, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y usos de la misma |
| WO2010147665A1 (en) | 2009-06-19 | 2010-12-23 | Teva Pharmaceutical Industries Ltd. | Treatment of multiple sclerosis with laquinimod |
| ME02414B (me) * | 2009-07-30 | 2016-09-20 | Teva Pharma | Tretman kronove bolesti lakvinimodom |
| AU2010282948C1 (en) | 2009-08-10 | 2017-03-02 | Active Biotech, Ab | Treatment of BDNF-related disorders using laquinimod |
| DE102010026879A1 (de) * | 2010-02-11 | 2011-08-11 | AMW GmbH, 83627 | Transdermales System mit Immunmodulator |
| EP2542080B1 (en) | 2010-03-03 | 2016-08-31 | Teva Pharmaceutical Industries Ltd. | Treatment of lupus arthritis using laquinimod |
| KR20160129093A (ko) | 2010-03-03 | 2016-11-08 | 테바 파마슈티컬 인더스트리즈 리미티드 | 라퀴니모드를 이용한 루푸스 신장염의 치료 |
| CA2791709A1 (en) | 2010-03-03 | 2011-09-09 | Teva Pharmaceutical Industries Ltd. | Treatment of rheumatoid arthritis with a combination of laquinimod and methotrexate |
| MX2013000333A (es) | 2010-07-09 | 2013-02-26 | Teva Pharma | N-etil-n-fenil-1,2-dihidro-4-hidroxi-5-cloro-1-metil-2-oxoquinoli na-3-carboxamida deuterada, sales y usos de la misma. |
| JP5934202B2 (ja) | 2010-07-09 | 2016-06-15 | テバ ファーマシューティカル インダストリーズ リミティド | ５−クロロ−４−ヒドロキシ−１−メチル−２−オキソ−ｎ−フェニル−１，２−ジヒドロキノリン−３−カルボキサミドと、その塩及びその使用 |
| EP2648732A4 (en) | 2010-12-07 | 2014-04-30 | Teva Pharma | USE OF LAQUINIMOD TO REDUCE TEMPERATURE, IMPROVE FUNCTIONAL STATUS AND IMPROVE LIFE QUALITY IN PATIENTS WITH MULTIPLE SCLEROSIS |
| WO2012131539A1 (en) | 2011-03-31 | 2012-10-04 | Pfizer Inc. | Novel bicyclic pyridinones |
| SG10201606204TA (en) | 2011-07-28 | 2016-09-29 | Teva Pharma | Treatment Of Multiple Sclerosis With Combination Of Laquinimod And Interferon-Beta |
| MX2014001050A (es) | 2011-07-28 | 2014-04-14 | Teva Pharma | Tratamiento de esclerosis multiple con combinacion de laquinimod y acetato de glatiramero. |
| HK1199820A1 (en) | 2011-10-12 | 2015-07-24 | Teva Pharmaceutical Industries Ltd. | Treatment of multiple sclerosis with combination of laquinimod and fingolimod |
| EP2744498A4 (en) | 2012-02-16 | 2014-12-03 | Teva Pharma | N-ETHYL-N-PHENYL-1,2-DIHYDRO-4,5-DI-HYDROXY-1-METHYL-2-OXO-3-CHINOLINE CARBOXAMIDE AND THE PREPARATION AND USE THEREOF |
| US20130259856A1 (en) | 2012-03-27 | 2013-10-03 | Teva Pharmaceutical Industries, Ltd. | Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarate |
| TW201347762A (zh) | 2012-05-02 | 2013-12-01 | Teva Pharma | 高劑量拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）於治療多發性硬化症之用途 |
| TW201350467A (zh) | 2012-05-08 | 2013-12-16 | Teva Pharma | Ｎ－乙基－４－羥基－１－甲基－５－（甲基（２，３，４，５，６－五羥基己基）胺基）－２－側氧－ｎ－苯基－１，２－二氫喹啉－３－甲醯胺 |
| TW201400117A (zh) | 2012-06-05 | 2014-01-01 | Teva Pharma | 使用拉喹莫德治療眼發炎疾病 |
| WO2014004733A1 (en) | 2012-06-26 | 2014-01-03 | The Regents Of The University Of California | Composition for lupus nephritis and methods of making and using the same |
| AR091706A1 (es) | 2012-07-11 | 2015-02-25 | Teva Pharma | Formulaciones de laquinimod sin agentes alcalinizantes |
| UY34896A (es) | 2012-07-12 | 2014-02-28 | Teva Pharma | Tratamiento de la esclerosis múltiple con una combinación de laquinimod y fampridina |
| TW201410244A (zh) | 2012-08-13 | 2014-03-16 | Teva Pharma | 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ） |
| TW201410243A (zh) | 2012-08-13 | 2014-03-16 | Teva Pharma | 用於治療大麻素受體型１（ｃｂ１）媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ） |
| CN105263325A (zh) | 2012-10-12 | 2016-01-20 | 梯瓦制药工业有限公司 | 用于降低多发性硬化症中丘脑损伤的拉喹莫德 |
| HK1215210A1 (zh) | 2012-11-07 | 2016-08-19 | Teva Pharmaceutical Industries Ltd. | 拉喹莫德胺盐 |
| US20140235670A1 (en) | 2013-02-15 | 2014-08-21 | Teva Pharmaceutical Industries, Ltd. | Treatment of progressive forms of multiple sclerosis with laquinimod |
| HK1220125A1 (zh) | 2013-03-14 | 2017-04-28 | Teva Pharmaceutical Industries Ltd. | 拉喹莫德的透皮配方 |
| CA2901849A1 (en) | 2013-03-14 | 2014-09-25 | Teva Pharmaceutical Industries Ltd. | Crystals of laquinimod sodium and improved process for the manufacture thereof |
| EP3094330A4 (en) * | 2014-01-17 | 2017-09-27 | Teva Pharmaceutical Industries Ltd | Treatment of crohn's disease using low doses of laquinimod |
-
2013
- 2013-02-01 AR ARP130100296A patent/AR089862A1/es unknown
- 2013-02-01 MX MX2014009373A patent/MX2014009373A/es unknown
- 2013-02-01 JP JP2014555758A patent/JP2015505564A/ja not_active Withdrawn
- 2013-02-01 CN CN201380007766.6A patent/CN104093310A/zh active Pending
- 2013-02-01 HK HK15103524.2A patent/HK1202776A1/xx unknown
- 2013-02-01 CA CA2862865A patent/CA2862865A1/en not_active Abandoned
- 2013-02-01 TW TW102104087A patent/TW201345527A/zh unknown
- 2013-02-01 EA EA201491460A patent/EA201491460A1/ru unknown
- 2013-02-01 CN CN201610357641.1A patent/CN106063787A/zh active Pending
- 2013-02-01 WO PCT/US2013/024356 patent/WO2013116657A1/en not_active Ceased
- 2013-02-01 US US13/757,004 patent/US9161935B2/en active Active
- 2013-02-01 EP EP13744015.2A patent/EP2811832A4/en not_active Withdrawn
- 2013-02-01 BR BR112014018485A patent/BR112014018485A8/pt not_active IP Right Cessation
- 2013-02-01 KR KR1020147024856A patent/KR20140138694A/ko not_active Withdrawn
- 2013-02-01 SG SG11201404214QA patent/SG11201404214QA/en unknown
- 2013-02-01 AU AU2013214909A patent/AU2013214909A1/en not_active Abandoned
-
2014
- 2014-07-08 IL IL233557A patent/IL233557A0/en unknown
-
2015
- 2015-08-25 US US14/835,123 patent/US20150359788A1/en not_active Abandoned
-
2017
- 2017-01-24 AU AU2017200472A patent/AU2017200472A1/en not_active Abandoned
- 2017-05-26 JP JP2017104049A patent/JP2017200926A/ja not_active Withdrawn
- 2017-06-26 US US15/633,132 patent/US20170290822A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2017200926A (ja) | 2017-11-09 |
| CN104093310A (zh) | 2014-10-08 |
| SG11201404214QA (en) | 2014-08-28 |
| JP2015505564A (ja) | 2015-02-23 |
| US20150359788A1 (en) | 2015-12-17 |
| EP2811832A1 (en) | 2014-12-17 |
| HK1202776A1 (en) | 2015-10-09 |
| US9161935B2 (en) | 2015-10-20 |
| CA2862865A1 (en) | 2013-08-08 |
| EP2811832A4 (en) | 2015-09-23 |
| BR112014018485A2 (enExample) | 2017-06-20 |
| US20130203807A1 (en) | 2013-08-08 |
| AR089862A1 (es) | 2014-09-24 |
| AU2017200472A1 (en) | 2017-02-09 |
| BR112014018485A8 (pt) | 2017-07-11 |
| AU2013214909A1 (en) | 2014-09-18 |
| TW201345527A (zh) | 2013-11-16 |
| US20170290822A1 (en) | 2017-10-12 |
| KR20140138694A (ko) | 2014-12-04 |
| IL233557A0 (en) | 2014-08-31 |
| WO2013116657A1 (en) | 2013-08-08 |
| MX2014009373A (es) | 2014-08-27 |
| CN106063787A (zh) | 2016-11-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201491460A1 (ru) | ПРИМЕНЕНИЕ ЛАХИНИМОДА В ЛЕЧЕНИИ ПАЦИЕНТОВ С БОЛЕЗНЬЮ КРОНА, У КОТОРЫХ НЕ ЭФФЕКТИВНА ТЕРАПИЯ ПЕРВОЙ ЛИНИИ АНТИ-TNFα | |
| MX2022015499A (es) | Metodos para tratar la enfermedad de crohn y la colitis ulcerosa. | |
| MX2011007854A (es) | Metodos para tratar infartos agudos al miocardio y trastornos relacionados. | |
| EA201690069A1 (ru) | Применение высоких доз придопидина для лечения болезни хантингтона | |
| EA201270221A1 (ru) | Лечение болезни крона с применением лаквинимода | |
| MX2020004023A (es) | Uso de un inhibidor de pcsk9 para tratar la hiperlipidemia. | |
| EA201490163A1 (ru) | Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения | |
| EA201790406A1 (ru) | Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения | |
| RU2014150942A (ru) | Лечение побочных эффектов в виде моторных и двигательных расстройств, связанных с лечением болезни паркинсона | |
| AR109103A1 (es) | Tratamiento de la enfermedad de fabry en pacientes no tratados y tratados previamente con ert | |
| EA201590654A1 (ru) | Комбинация разагилина и придопидина для лечения нейродегенеративных нарушений, в частности болезни хантингтона | |
| MA33991B1 (fr) | Procede de traitement des troubles de l'angiogenese oculaire ou de la fuite vasculaire | |
| MX2015006120A (es) | Compuestos novedosos oralmente biodisponibles que modulan el control de la respiracion, y metodos de uso de los mismos. | |
| MX2017006938A (es) | Terapia de combinacion para el tratamiento de cancer. | |
| MX2008013635A (es) | Utilizacion de albumina humana terapeutica para la preparacion de un medicamento para el tratamiento de pacientes afectados por desordenes cognitivos. | |
| EA201790352A1 (ru) | Терапевтическое лечение на основе анаморелина | |
| RU2012108656A (ru) | Применение 4-аминопиридина для улучшения состояния при нейрокогнитивном и/или нейропсихиатрическом нарушении у пациентов с демиелинизирующими и другими заболеваниями нервной системы | |
| BR112013029182A2 (pt) | método para o tratamento de malignidades sólidas incluindo malignidades sólidas avançadas ou metastáticas | |
| RU2017105837A (ru) | Лечение приливов и потери костной ткани, вызванных андрогенной депривационной терапией, с применением цис-кломифена | |
| RU2013104381A (ru) | Лечение отслойки васкуляризированного пигментного эпителия терапевтическим средством против vegf | |
| EA202193276A1 (ru) | Способы лечения холангиокарциномы | |
| JP2016504361A5 (enExample) | ||
| UA109359C2 (xx) | Лікування захворювань і станів шкіри 7-(1h-імідазол-4-ілметил)-5,6,7,8-тетрагідрохіноліном | |
| MY169320A (en) | Method and device for treating blood cholesterol disorders | |
| HK1225969A1 (zh) | 利用低剂量的拉喹莫德治疗克隆氏病 |